BioNTech (BNTX)
(Delayed Data from NSDQ)
$96.95 USD
-2.05 (-2.07%)
Updated May 24, 2024 04:00 PM ET
After-Market: $96.82 -0.13 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
BNTX 96.95 -2.05(-2.07%)
Will BNTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BNTX
Why Earnings Season Could Be Great for BioNTech (BNTX)
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
Other News for BNTX
Moderna Was Among The Best Performing Large-Cap Stocks Last Week (May 20-May 26, 2024): Are They In Your Portfolio?
Buy Rating on BioNTech SE Amidst Undervaluation and Strong Pipeline Prospects
Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More
Biotech Alert: Searches spiking for these stocks today
Critical Insights From BioNTech Analyst Ratings: What You Need To Know